BIIB

BIIB

USD

Biogen Inc. Common Stock

$134.210+1.165 (0.876%)

Real-time Price

Healthcare
Drug Manufacturers - General
United States

Price Chart

Loading Chart...

Key Metrics

Market Metrics
Company Fundamentals
Trading Stats

Market Metrics

Open

$133.045

High

$134.590

Low

$132.370

Volume

1.14M

Company Fundamentals

Market Cap

19.7B

Industry

Drug Manufacturers - General

Country

United States

Trading Stats

Avg Volume

1.50M

Exchange

NMS

Currency

USD

52-Week Range

Low $110.04Current $134.210High $236.48

Related News

GlobeNewswire

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies specifically approved

View more
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy
GlobeNewswire

New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA®

View more
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA
Analyst Upgrades

RBC Capital Reiterates Outperform on Biogen, Maintains $213 Price Target

RBC Capital analyst Brian Abrahams reiterates Biogen with a Outperform and maintains $213 price target.

View more
RBC Capital Reiterates Outperform on Biogen, Maintains $213 Price Target
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $187 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates Biogen with a Buy and maintains $187 price target.

View more
HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $187 Price Target
GlobeNewswire

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA

View more
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Analyst Upgrades

Piper Sandler Reiterates Neutral on Biogen, Maintains $115 Price Target

Piper Sandler analyst David Amsellem reiterates Biogen with a Neutral and maintains $115 price target.

Analyst Upgrades

Wedbush Reiterates Neutral on Biogen, Maintains $121 Price Target

Wedbush analyst Laura Chico reiterates Biogen with a Neutral and maintains $121 price target.